Synta Pharmaceuticals Corp $3.98

down -0.05


20/8/2014 04:00 PM  |  NASDAQ : SNTA  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get SNTA Trend Analysis - it has underperformed the S&P 500 by 51%

Partner Headlines

  1. Synta Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML ...

    Benzinga
  2. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  3. 5-Star Biotech Stock Watch: Synta Pharmaceuticals

    Benzinga
  4. 3 Biotech Stocks Backed By Big Money

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Top Trending Tickers On StockTwits For March 12

    Benzinga
  8. Morning Movers for March 12th, 2014

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. UPDATE: Stifel Downgrades Synta Pharmaceuticals as GALAXY-2 Adjustments ...

    Benzinga
  12. Earnings Scheduled For March 11, 2014

    Benzinga
  13. Stocks Hitting 52-Week Lows

    Benzinga
  14. Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock ...

    Benzinga
  15. Synta Presents Positive One-Year Follow-up Results for GALAXY-1 Trial of ...

    Benzinga
  16. Synta Announces Encouraging Results of Ganetespib GALAXY-1 Trial at ECC ...

    Benzinga
  17. Shares of Synta Moving Higher Following News of Fast Track Designation ...

    Benzinga
  18. These Three Speculative Companies Are Loved By Insiders and Institutions

    Benzinga
  19. Synta Provides Clinical Updates

    Benzinga
  20. Synta Provides Clinical Updates

    Benzinga
  21. Market Wrap for Monday, July 29: Stocks Record Moderate Losses to Start ...

    Benzinga
  22. Synta Pharmaceuticals Surges 45% on Positive ENCHANT-1 Breast Cancer Results

    Benzinga
  23. Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second ...

    Benzinga
  24. Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares

    GuruFocus
  25. Synta Pharmaceuticals, Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares

    GuruFocus
  26. Synta Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  27. UPDATE: Jefferies Raises PT to $22 on Synta Pharmaceuticals on GALAXY Update

    Benzinga
  28. UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm ...

    Benzinga
  29. Synta Announces $25.8 Million Registered Direct Offering of Common Stock

    Benzinga
  30. Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI

    GuruFocus
  31. Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares

    GuruFocus
  32. Health Care Sector Wrap

    FoxBusiness
  33. Synta Pharmaceuticals (SNTA) Up 15% after Jefferies Issues Bullish Note

    MarketIntelligenceCenter
  34. UPDATE: Jefferies Raises PT on Synta from $7 to $14

    Benzinga
  35. Teva Pharmaceutical Industries, Constellation Brands Among Stocks Up on ...

    FoxBusiness
  36. Quest Software, Pharmacyclics, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness
  37. Merck &, Onyx Pharmaceuticals Among Stocks Hitting 52-Week Highs Friday

    FoxBusiness
  38. UPDATE: BMO Capital Markets Upgrades Synta Pharmaceuticals to Outperform ...

    Benzinga
  39. Benzinga's Top Pre-Market Losers

    Benzinga
  40. Today's Top Small-Cap Winners!

    Benzinga
  41. UPDATE: Jefferies Initiates Coverage on Synta Pharmaceuticals

    Benzinga
  42. Synta Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus
  43. Earnings Scheduled For February 22

    Benzinga
  44. These 4 Biotech Stocks Are a Buy Now

    GuruFocus
  45. Notable Put Options Activity in Synta Pharmaceuticals

    Benzinga
  46. UPDATE: Synta Prices 7M Shares at $4.40 Each

    Benzinga
  47. McNicoll Lewis & Vlak Reiterates Buy, $10 Target on Synta Pharmaceuticals

    Benzinga
Trading Center